Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 301 BINNEY STREET CAMBRIDGE MA 02142 |
Tel: | N/A |
Website: | https://generationbio.com |
IR: | See website |
Key People | ||
Cameron Geoffrey Mcdonough President, Chief Executive Officer, Director | Matthew Norkunas Chief Financial Officer | Antoinette Paone Chief Operating Officer |
Matthew Stanton Chief Scientific Officer | Phillip Samayoa Chief Strategy Officer | Yalonda Howze Chief Legal Officer, Secretary |
Business Overview |
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases. |
Financial Overview |
For the three months ended 31 March 2024, Generation Bio Co revenues increased from $0K to $4.1M. Net loss increased from $32.1M to $74.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.53 to -$1.12. |
Employees: | 174 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $15.54M as of Mar 31, 2024 |
Annual revenue (TTM): | $9.96M as of Mar 31, 2024 |
EBITDA (TTM): | -$119.16M as of Mar 31, 2024 |
Net annual income (TTM): | -$169.06M as of Mar 31, 2024 |
Free cash flow (TTM): | -$65.33M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 66,528,840 as of May 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |